^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GPRC5D inhibitor

    Related drugs:
    3d
    CREATT: Multi-center, Observational Study of Teclistamab or Talquetamab in The Treatment of Multiple Myeloma Patients in China (ChiCTR2500112479)
    P4, N=200, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New P4 trial
    |
    Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    14d
    OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
    P2, N=100, Recruiting, SCRI Development Innovations, LLC | N=75 --> 100
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    29d
    Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=31, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    1m
    CR109234: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Aug 2028
    Trial completion date • First-in-human
    |
    JNJ-5322
    1m
    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2028 --> Nov 2027
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • JNJ-5322
    1m
    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov)
    P2, N=160, Recruiting, University of Heidelberg Medical Center | Trial completion date: Aug 2028 --> Sep 2029 | Trial primary completion date: Feb 2027 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • JNJ-5322 • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=157, Not yet recruiting, Janssen Research & Development, LLC
    New P2 trial
    |
    JNJ-5322
    2ms
    Trilogy-4: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    JNJ-5322 • Tecvayli (teclistamab-cqyv)
    3ms
    MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    3ms
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Oct 2025 --> Apr 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    3ms
    Combination Therapy with QLS32015 for the Treatment of Multiple Myeloma (ChiCTR2500107567)
    P2, N=160, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology
    New P2 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • QLS32015
    3ms
    OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
    P2, N=75, Recruiting, SCRI Development Innovations, LLC | Trial completion date: Mar 2026 --> Oct 2027 | Trial primary completion date: Feb 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)